Disc Medicine Inc. (NASDAQ: IRON) presented updated data from its RALLY-MF Phase 2 trial of DISC-0974 for myelofibrosis-associated anemia at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE